MARATTO

article · BMC Psychiatry

Unexpected resolution of clozapine-induced obsessive–compulsive symptoms with cariprazine augmentation: a case report

Abstract

The management of obsessive–compulsive symptoms (OCS) in patients with schizophrenia is challenging, as many antipsychotics can induce OCS. Increasing evidence supports the use of partial agonists in managing these cases. This case report describes a patient with treatment-resistant schizophrenia and clozapine-induced obsessive–compulsive symptoms who underwent multiple antipsychotic regimens without significant improvement. The patient's symptoms progressed gradually, and their condition was managed entirely on an outpatient basis. Despite multiple adjustments to antipsychotic medications (risperidone, then haloperidol, then aripiprazole), the patient showed only a partial response to treatment, leading to their classification as treatment-resistant. Due to the lack of adequate response, the medical team decided to prescribe clozapine. However, at a dose of 350 mg, clozapine triggered compulsive checking and washing behaviors. Consequently, the team initiated treatment with a third-generation antipsychotic, cariprazine, at a dose of 6 mg, combined with sertraline at 100 mg while gradually reducing clozapine. Unexpectedly, there was a significant improvement in both psychotic symptoms and OCS. The combination of cariprazine, as a D3 partial agonist, with clozapine may be an effective approach for managing challenging cases of treatment-resistant schizophrenia associated with de novo OCS.

Research topics

  • Obsessive-Compulsive Spectrum Disorders
  • Schizophrenia research and treatment
  • Electroconvulsive Therapy Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s12888-025-07232-1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.